Wolverine legal status, the FDA 503A category, and compounding access for the BPC-157 TB-500 blend.

The forward-leaning headline: access is under active FDA review

The most important thing about the Wolverine legal status right now is that it is in motion. Both components of the BPC-157 TB-500 blend are under active FDA review for compounding access, and that access may expand in 2026. The concrete, citable anchor for that momentum is a scheduled event: the FDA's Pharmacy Compounding Advisory Committee (PCAC) is set to meet on July 23-24, 2026 to discuss BPC-157 and TB-500, among other peptides, as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[13].

Read that precisely. A PCAC meeting is a scheduled discussion of substances under evaluation. It is advisory, not a decision; inclusion on a final bulks list is decided by FDA rulemaking, and a committee discussion is one step in that evaluation, not its outcome ^[14]. No reclassification has occurred, none is dated, and none is certain. What is true today is that the question is open and on the FDA's calendar — which is a meaningfully different posture from a closed door.

This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance.

The current fact: both components are in FDA 503A Category 2

As of today, the present-tense regulatory fact is restrictive. Drug compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act: Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians; Section 503B covers FDA-registered outsourcing facilities compounding in larger volumes ^[14]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list ^[14].

Neither BPC-157 nor TB-500 meets that bar today. The FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[12]. In the same update, the FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2, citing potential immunogenicity for certain routes and a lack of important safety information; the FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 ^[12].

Category 2 matters because of what it withholds: per FDA's interim policy, Category 2 substances are those nominated with sufficient information to evaluate but identified as raising significant safety risks, and they are not covered by the enforcement-discretion policy that applies to Category 1 — the FDA stated it would consider taking action against a compounder who compounds with a Category 2 substance ^[12]. So compounding-pharmacy access to both BPC-157 and TB-500 is currently restricted. Neither is an FDA-approved drug, and the assembled blend has no approved therapeutic indication.

No component carve-out: both peptides are on the July 2026 PCAC agenda

There is no split decision available here. Both of Wolverine's components — BPC-157 and TB-500, the thymosin beta-4 fragment LKKTETQ — are currently in Category 2, and both are named on the published agenda of the same scheduled review ^[12][13]. The FDA's public calendar lists BPC-157 (as "BPC-157 (free base)" / "BPC-157 acetate") and TB-500 (as "TB-500 (free base)" / "TB-500 acetate") among the bulk drug substances being considered for inclusion on the 503A bulks list at the July 23-24, 2026 PCAC meeting ^[13].

Neither peptide has a separate, more permissive status; neither is carved out of the current restriction or the upcoming review. They entered Category 2 together in 2023 ^[12], and they are under the same scheduled evaluation in 2026 ^[13]. Whatever the committee discusses, it discusses for both. And again — that discussion is an evaluation step, not a listing, a reclassification, or a dated outcome ^[14].

How legally compounded peptide access works

In general terms, lawful access to a compounded medication in the U.S. follows a defined pathway, and it is worth understanding before any specific substance enters the picture ^[14].

First, an individual patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. Telehealth functions here as a front-end channel to that prescriber consultation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[14]. Second, if appropriate and lawful, the prescriber issues a valid, patient-specific prescription. Third, that prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[14].

The caveat sits on top of all three steps: the compounder may use the requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[14]. For BPC-157 and TB-500, that is the current state — which is exactly why their place on the July 2026 review agenda is the part of the file worth watching ^[13]. This is a description of how the framework works in general; it names no pharmacy, clinic, telehealth provider, or vendor, and it is not guidance on obtaining any substance.

Access and regulatory questions